The anti-IL-6R antibodies tocilizumab and sarilumab and the anti-IL-6 antibody siltuximab are currently being tested in 13 clinical trials for efficacy in managing COVID-19 CSS and pneumonia [55]. Here, IL6 is linked to COVID-19.